QT Prolongation Risk Comparison

The European Heart Journal guidelines suggest that metoclopramide is not listed among medications with known QT prolongation risk, and it can be considered the safest option among these three antiemetics when QT prolongation is a primary concern 1, 2
Ondansetron causes QT prolongation through inhibition of cardiac hERG K+ channels, which is dose-dependent 1
Prochlorperazine belongs to the phenothiazine class of antipsychotics, which are associated with QT prolongation, and the European Heart Journal recommends avoiding certain antipsychotics including phenothiazines in patients with prolonged QT 2, 3

Female gender and age >65 years significantly increase the risk of QT prolongation 2
Baseline QTc >500 ms represents a high-risk situation requiring extreme caution 3
Electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, exponentially increase torsades de pointes risk 2, 3

Clinical Management

For patients with normal baseline QTc, metoclopramide is the preferred first-line agent with minimal QT risk 1, 2
For patients with prolonged QTc (≥500 ms), avoid ondansetron and prochlorperazine entirely, and metoclopramide can be used safely with standard precautions 2, 3

Obtain baseline ECG before initiating prochlorperazine therapy, and perform follow-up ECG after dose titration 2, 4
Discontinue prochlorperazine immediately if QTc exceeds 500 ms or increases by >60 ms from baseline 4
Standard monitoring is sufficient for metoclopramide, with no special ECG monitoring required specifically for QT concerns 1, 2